The development of therapeutic antibodies targeting the GM-CSF receptor α-chain offers a valuable opportunity to test the importance of GM-CSF in JIA pathology, and early reports from rheumatoid arthritis studies are encouraging (19). The gene discussed is CSF2; the disease is juvenile idiopathic arthritis.